Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Ptc Therapeutics stock hits 52-week low at $58.57

Ptc Therapeutics stock hits 52-week low at $58.57

PTC Therapeutics Inc. stock sank to a 52-week low of $58.57, just a penny shy of its yearly low of $58.80. This marks a troubling 20.7% decline for the year for the biopharmaceutical company, which is valued at $4.93 billion. The business reported a $1.16 billion revenue for the past year, but it still faces hurdles despite boasting a robust gross profit margin of 55.18%.

According to InvestingPro analysis, the stock seems underpriced at present, and experts anticipate the firm will turn profitable again this year. Investors can delve into more information via InvestingPro’s detailed Pro Research Report, which simplifies intricate financial data into practical insights for PTCT and over 1,400 other US equities.

In a separate development, PTC Therapeutics disclosed a revenue of $357.8 million in the third quarter of 2026, exceeding Wall Street’s forecast of $304.05 million. However, the firm reported a loss of $0.62 per share, sharply contrasting the expected profit of $0.30 per share. This revenue surge was fueled by robust demand for SEPHIENCE and royalty income from Evrysdi.

Truist Securities maintained a Hold rating on PTC Therapeutics with a price target of $62.00 after examining the quarterly results. Management expressed optimism about the SEPHIENCE launch transitioning into a more mature growth phase. These recent events have piqued investor interest, as they grapple with the company's strong sales against its earnings shortfall. This report was produced with AI assistance and edited by a human.

Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at investing.com →

More in Finance & Markets

Pure Cycle (PCYO) Q4 2026 Earnings Call Transcript

Industrial water demand surged while the rental portfolio gets wound down.

  • Pure Cycle reported $14.2M net income for FY 2026
  • Top-line growth from record land development and water deliveries
  • Strategic shift to exit single-family rentals, focus on water/land assets

If I Were Building a Portfolio From Scratch With $10,000, These 3 Consumer Stocks Would Come First

Of course, these are also some of the simplest but most reliable names that plenty of experienced investors with long-lived portfolios are also holding.

  • Coca-Cola (KO) offers 2.1% dividend yield and 64 years of consecutive dividend growth
  • Walmart (WMT) invests in growth through stock buybacks despite low 0.9% dividend yield
  • Procter & Gamble (PG) has raised dividend for 70+ years with 2.5% yield and strong market position

Correcting the TV ad market’s imperfect shift to streaming

Evan Rutchik, president and Chief Strategy Officer, Viamedia.ai The TV ad industry’s shift from linear to streaming is real, but the financial truth underlying that shift may not align with many people’s perception of the transition. That’s because the movement of ad budgets from linear to streaming has hardly been evenly paced.

More from Thursday 19 November →